Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Bristol-Myers Squibb (BMY) is trading at $60.72, down 0.71% on the day. Its market value of $124.02B makes it the 122nd largest of the 300 companies we follow.
Over the past 52 weeks it has traded between $41.13 and $68.64, so it sits 11.5% below the top of that range. Holders are ahead 44.1% over twelve months, and up 11.6% across the last three months.
Price is below the 50-day average ($64.27) but above the 200-day ($58.30); RSI is 36, and the last 30 sessions moved at roughly 22% annualized volatility.
In the quarter ended Jun 2026 the company brought in $12.97B of revenue, up 5.7% from a year earlier, with $3.32B of net profit (a 18.9% margin).
Buyers are paying 13.4 times trailing earnings, 52% above its five-year average of 8.8. The median for its industry group is 20.4.
18 analysts follow the stock and the average call is "buy". The mean target, $67.88, sits 11.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Bristol Myers Squibb sells cancer, blood, immunology and heart drugs, including Eliquis and Opdivo, both facing patent expiries.
What tends to move it. The main question is whether newer products can offset the loss of exclusivity on its biggest sellers later this decade.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -6.4% | Bearish |
| Price vs 50-day average | -5.5% | Bearish |
| Price vs 200-day average | +4.1% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 35.7 | Bearish |
| MACD (12,26,9) | -0.66 | Bearish |
| Bollinger band position | -1% | Neutral |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Below its usual level · 38th percentile, 5-year average 8.8x
#1011 of 2975 stocks by PE (1 = cheapest)
Above its usual level · 74th percentile, 5-year average 5.1x
#4443 of 5302 stocks by PB (1 = cheapest)
Around its usual level · 56th percentile, 5-year average 2.6x
#2843 of 5141 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: −$8.76M (8 inflow days, 12 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 6.8% a year.
$60.72 is the latest print for BMY, a move of -0.71% against yesterday's close of $61.15. Today's low and high so far: $60.60 and $61.57.
Equity value comes to $124.02B at the current price. By that measure it is number 122 of the 300 names in our coverage.
Buyers pay 13.4 times the last twelve months of profit (EPS $3.46). Averaged over five years the multiple has been 8.8, and today's level ranks in the 38th percentile of its own history.
The year's floor is $41.13 and the ceiling $68.64. Shares are 11.5% away from that ceiling.
It does. Payouts over the past twelve months work out to a 4.13% yield; the latest ex-dividend date was July 2, 2026.
Of 18 analysts, 44% say buy, 50% hold and 6% sell. Price targets average $67.88, with the most cautious at $40.00 and the most optimistic at $82.00.
Bristol Myers Squibb sells cancer, blood, immunology and heart drugs, including Eliquis and Opdivo, both facing patent expiries.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.